Efficacy Study of Additional Chemotherapy After Concurrent Chemoradiation in Non-small Cell Lung Cancer
Status:
Completed
Trial end date:
2015-05-01
Target enrollment:
Participant gender:
Summary
Non-Small Cell Lung Cancer(NSCLC) is the leading cause of death in Korean men after stomach
cancer. Surgical resection plays a main role for curative treatment. However, less than 20 %
of the NSCLC patients have been found in stage I-II disease. In inoperable stage IIIA/B
disease, the recommended treatment is combined chemotherapy and radiation therapy. Various
kinds of combination of 2 modalities have been used either in sequential or concurrent
setting. Concurrent chemoradiotherapy(CCRT) have been recognized to have better survival than
radiation therapy alone or sequential therapy, but additional consolidation chemotherapy
after CCRT is not yet to be determined for the beneficial role in survival gain. Docetaxel is
an anticancer drug and has synergistic anticancer effect in various cancer with cisplatin,
another anticancer drug. In the present study, randomised trial will be performed to confirm
the efficacy of the consolidation chemotherapy with docetaxel and cisplatin after completing
CCRT with the same chemotherapeutic agents in stage III inoperable NSCLC on progression free
survival and overall survival.